Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs

Identifieur interne : 002760 ( Pmc/Corpus ); précédent : 002759; suivant : 002761

Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs

Auteurs : Dominique Kyelem ; Gautam Biswas ; Moses J. Bockarie ; Mark H. Bradley ; Maged El-Setouhy ; Peter U. Fischer ; Ralph H. Henderson ; James W. Kazura ; Patrick J. Lammie ; Sammy M. Njenga ; Eric A. Ottesen ; Kapa D. Ramaiah ; Frank O. Richards ; Gary J. Weil ; Steven A. Williams

Source :

RBID : PMC:2694403

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000. To understand why some national programs have been more successful than others, a panel of individuals with expertise in LF elimination efforts met to assess available data from programs in 8 countries. The goal was to identify: 1) the factors determining success for national LF elimination programs (defined as the rapid, sustained reduction in microfilaremia/antigenemia after repeated mass drug administration [MDA]); 2) the priorities for operational research to enhance LF elimination efforts.

Of more than 40 factors identified, the most prominent were 1) initial level of LF endemicity; 2) effectiveness of vector mosquitoes; 3) MDA drug regimen; 4) population compliance.

Research important for facilitating program success was identified as either biologic (i.e., [1] quantifying differences in vectorial capacity; [2] identifying seasonal variations affecting LF transmission) or programmatic (i.e., [1] identifying quantitative thresholds, especially the population compliance levels necessary for success, and the antigenemia or microfilaremia prevalence at which MDA programs can stop with minimal risk of resumption of transmission; [2] defining optimal drug distribution strategies and timing; [3] identifying those individuals who are “persistently non-compliant” during MDAs, the reasons for this non-compliance and approaches to overcoming it).

While addressing these challenges is important, many key determinants of program success are already clearly understood; operationalizing these as soon as possible will greatly increase the potential for national program success.


Url:
PubMed: 18840733
PubMed Central: 2694403

Links to Exploration step

PMC:2694403

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs</title>
<author>
<name sortKey="Kyelem, Dominique" sort="Kyelem, Dominique" uniqKey="Kyelem D" first="Dominique" last="Kyelem">Dominique Kyelem</name>
</author>
<author>
<name sortKey="Biswas, Gautam" sort="Biswas, Gautam" uniqKey="Biswas G" first="Gautam" last="Biswas">Gautam Biswas</name>
</author>
<author>
<name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name>
</author>
<author>
<name sortKey="Bradley, Mark H" sort="Bradley, Mark H" uniqKey="Bradley M" first="Mark H." last="Bradley">Mark H. Bradley</name>
</author>
<author>
<name sortKey="El Setouhy, Maged" sort="El Setouhy, Maged" uniqKey="El Setouhy M" first="Maged" last="El-Setouhy">Maged El-Setouhy</name>
</author>
<author>
<name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U." last="Fischer">Peter U. Fischer</name>
</author>
<author>
<name sortKey="Henderson, Ralph H" sort="Henderson, Ralph H" uniqKey="Henderson R" first="Ralph H." last="Henderson">Ralph H. Henderson</name>
</author>
<author>
<name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name>
</author>
<author>
<name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J." last="Lammie">Patrick J. Lammie</name>
</author>
<author>
<name sortKey="Njenga, Sammy M" sort="Njenga, Sammy M" uniqKey="Njenga S" first="Sammy M." last="Njenga">Sammy M. Njenga</name>
</author>
<author>
<name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A." last="Ottesen">Eric A. Ottesen</name>
</author>
<author>
<name sortKey="Ramaiah, Kapa D" sort="Ramaiah, Kapa D" uniqKey="Ramaiah K" first="Kapa D." last="Ramaiah">Kapa D. Ramaiah</name>
</author>
<author>
<name sortKey="Richards, Frank O" sort="Richards, Frank O" uniqKey="Richards F" first="Frank O." last="Richards">Frank O. Richards</name>
</author>
<author>
<name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J." last="Weil">Gary J. Weil</name>
</author>
<author>
<name sortKey="Williams, Steven A" sort="Williams, Steven A" uniqKey="Williams S" first="Steven A." last="Williams">Steven A. Williams</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">18840733</idno>
<idno type="pmc">2694403</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694403</idno>
<idno type="RBID">PMC:2694403</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">002760</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002760</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs</title>
<author>
<name sortKey="Kyelem, Dominique" sort="Kyelem, Dominique" uniqKey="Kyelem D" first="Dominique" last="Kyelem">Dominique Kyelem</name>
</author>
<author>
<name sortKey="Biswas, Gautam" sort="Biswas, Gautam" uniqKey="Biswas G" first="Gautam" last="Biswas">Gautam Biswas</name>
</author>
<author>
<name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name>
</author>
<author>
<name sortKey="Bradley, Mark H" sort="Bradley, Mark H" uniqKey="Bradley M" first="Mark H." last="Bradley">Mark H. Bradley</name>
</author>
<author>
<name sortKey="El Setouhy, Maged" sort="El Setouhy, Maged" uniqKey="El Setouhy M" first="Maged" last="El-Setouhy">Maged El-Setouhy</name>
</author>
<author>
<name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U." last="Fischer">Peter U. Fischer</name>
</author>
<author>
<name sortKey="Henderson, Ralph H" sort="Henderson, Ralph H" uniqKey="Henderson R" first="Ralph H." last="Henderson">Ralph H. Henderson</name>
</author>
<author>
<name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name>
</author>
<author>
<name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J." last="Lammie">Patrick J. Lammie</name>
</author>
<author>
<name sortKey="Njenga, Sammy M" sort="Njenga, Sammy M" uniqKey="Njenga S" first="Sammy M." last="Njenga">Sammy M. Njenga</name>
</author>
<author>
<name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A." last="Ottesen">Eric A. Ottesen</name>
</author>
<author>
<name sortKey="Ramaiah, Kapa D" sort="Ramaiah, Kapa D" uniqKey="Ramaiah K" first="Kapa D." last="Ramaiah">Kapa D. Ramaiah</name>
</author>
<author>
<name sortKey="Richards, Frank O" sort="Richards, Frank O" uniqKey="Richards F" first="Frank O." last="Richards">Frank O. Richards</name>
</author>
<author>
<name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J." last="Weil">Gary J. Weil</name>
</author>
<author>
<name sortKey="Williams, Steven A" sort="Williams, Steven A" uniqKey="Williams S" first="Steven A." last="Williams">Steven A. Williams</name>
</author>
</analytic>
<series>
<title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="ISSN">0002-9637</idno>
<idno type="eISSN">1476-1645</idno>
<imprint>
<date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="P1">The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000. To understand why some national programs have been more successful than others, a panel of individuals with expertise in LF elimination efforts met to assess available data from programs in 8 countries. The goal was to identify: 1) the factors determining success for national LF elimination programs (defined as the rapid, sustained reduction in microfilaremia/antigenemia after repeated mass drug administration [MDA]); 2) the priorities for operational research to enhance LF elimination efforts.</p>
<p id="P2">Of more than 40 factors identified, the most prominent were 1) initial level of LF endemicity; 2) effectiveness of vector mosquitoes; 3) MDA drug regimen; 4) population compliance.</p>
<p id="P3">Research important for facilitating program success was identified as either
<italic>biologic</italic>
(i.e., [1] quantifying differences in vectorial capacity; [2] identifying seasonal variations affecting LF transmission) or
<italic>programmatic</italic>
(i.e., [1] identifying quantitative thresholds, especially the population compliance levels necessary for success, and the antigenemia or microfilaremia prevalence at which MDA programs can stop with minimal risk of resumption of transmission; [2] defining optimal drug distribution strategies and timing; [3] identifying those individuals who are “persistently non-compliant” during MDAs, the reasons for this non-compliance and approaches to overcoming it).</p>
<p id="P4">While addressing these challenges is important, many key determinants of program success are already clearly understood; operationalizing these as soon as possible will greatly increase the potential for national program success.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0370507</journal-id>
<journal-id journal-id-type="pubmed-jr-id">473</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Trop Med Hyg</journal-id>
<journal-title>The American journal of tropical medicine and hygiene</journal-title>
<issn pub-type="ppub">0002-9637</issn>
<issn pub-type="epub">1476-1645</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">18840733</article-id>
<article-id pub-id-type="pmc">2694403</article-id>
<article-id pub-id-type="manuscript">NIHMS104991</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kyelem</surname>
<given-names>Dominique</given-names>
</name>
<xref rid="FN1" ref-type="author-notes">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Biswas</surname>
<given-names>Gautam</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bockarie</surname>
<given-names>Moses J.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bradley</surname>
<given-names>Mark H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El-Setouhy</surname>
<given-names>Maged</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fischer</surname>
<given-names>Peter U.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henderson</surname>
<given-names>Ralph H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kazura</surname>
<given-names>James W.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lammie</surname>
<given-names>Patrick J.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Njenga</surname>
<given-names>Sammy M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ottesen</surname>
<given-names>Eric A.</given-names>
</name>
<xref rid="FN1" ref-type="author-notes">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramaiah</surname>
<given-names>Kapa D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Richards</surname>
<given-names>Frank O.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weil</surname>
<given-names>Gary J.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Steven A.</given-names>
</name>
</contrib>
<aff id="A1">Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland; Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Department of Public Health, Ain Shams University, Cairo, Egypt; School of Medicine, Washington University, St. Louis, Missouri; Center for Global Health & Diseases, Case Western Reserve University, Cleveland, Ohio; Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Kenya Medical Research Institute, Nairobi, Kenya; Vector Control Research Centre, Indian Council of Medical Research, Pondicherry, India; Carter Center, Atlanta, Georgia; Clark Science Center, Smith College, Northampton, Massachusetts</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">
<label>*</label>
Address correspondence to Dominique Kyelem or Eric A. Ottesen, Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia. E-mails:
<email>dkyelem@taskforce.org</email>
and
<email>eottesen@taskforce.org</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>4</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>6</month>
<year>2009</year>
</pub-date>
<volume>79</volume>
<issue>4</issue>
<fpage>480</fpage>
<lpage>484</lpage>
<abstract>
<p id="P1">The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000. To understand why some national programs have been more successful than others, a panel of individuals with expertise in LF elimination efforts met to assess available data from programs in 8 countries. The goal was to identify: 1) the factors determining success for national LF elimination programs (defined as the rapid, sustained reduction in microfilaremia/antigenemia after repeated mass drug administration [MDA]); 2) the priorities for operational research to enhance LF elimination efforts.</p>
<p id="P2">Of more than 40 factors identified, the most prominent were 1) initial level of LF endemicity; 2) effectiveness of vector mosquitoes; 3) MDA drug regimen; 4) population compliance.</p>
<p id="P3">Research important for facilitating program success was identified as either
<italic>biologic</italic>
(i.e., [1] quantifying differences in vectorial capacity; [2] identifying seasonal variations affecting LF transmission) or
<italic>programmatic</italic>
(i.e., [1] identifying quantitative thresholds, especially the population compliance levels necessary for success, and the antigenemia or microfilaremia prevalence at which MDA programs can stop with minimal risk of resumption of transmission; [2] defining optimal drug distribution strategies and timing; [3] identifying those individuals who are “persistently non-compliant” during MDAs, the reasons for this non-compliance and approaches to overcoming it).</p>
<p id="P4">While addressing these challenges is important, many key determinants of program success are already clearly understood; operationalizing these as soon as possible will greatly increase the potential for national program success.</p>
</abstract>
<contract-num rid="AI1">U19 AI065717-04</contract-num>
<contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002760 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002760 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:2694403
   |texte=   Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:18840733" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024